00:02 , Jul 17, 2019 |  BC Extra  |  Company News

Abbisko builds combination strategy with China rights to X4's mavorixafor

Abbisko has licensed Greater China rights to X4’s mavorixafor, which the Shanghai-based company plans to use to develop a pipeline of combination therapies. The deal, for which financial terms are not disclosed, gives Abbisko Therapeutics...
19:34 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
18:45 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Scars/wrinkles Patient sample and mouse studies suggest inhibiting CXCL12 could help treat scars. In injured skin samples from scar patients, CXCL12 levels were higher in patients aged 40 years or younger with thick scars...
22:06 , Jun 14, 2018 |  BC Innovations  |  Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
19:11 , May 18, 2018 |  BC Week In Review  |  Clinical News

X4 reports additional Phase I/II data for RCC candidate

X4 Pharmaceuticals Inc. (Cambridge, Mass.) reported data from 22 evaluable patients with advanced clear cell renal cell carcinoma (RCC) in a Phase I/II trial showing that X4P-001-IO plus Inlyta axitinib led to an objective response...
17:57 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Polyphor reports Phase Ib data for breast cancer candidate

Polyphor Ltd. (Allschwill, Switzerland) reported data from an open-label, dose-escalation Phase Ib trial in 54 women with previously treated HER2-negative, CXC chemokine receptor 4 (CXCR4; NPY3R)-positive metastatic breast cancer showing that IV balixafortide (POL6326) plus...
20:09 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

X4 reports Phase II data for WHIM syndrome candidate

X4 Pharmceuticals Inc. (Cambridge, Mass.) reported preliminary data from five evaluable patients with warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome in the open-label, dose-escalation Phase II portion of the Phase II/III X4P-001-MKKA trial showing that...
21:53 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

BioLineRx reports additional Phase IIa data for BL-8040 in AML

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the expansion portion of a Phase IIa trial in 16 patients with relapsed or refractory acute myelogenous leukemia (AML) showing that BL-8040 as monotherapy for two days...
20:55 , Dec 19, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method to rapidly mobilize donor HSCs from the bone marrow to the blood by antagonizing CXCR4 and agonizing CXCR2 could be useful for HSCTs. In mice, subcutaneous injection of the CXCR4...
00:08 , Dec 9, 2017 |  BC Extra  |  Preclinical News

A faster method for harvesting HSCs for transplantation

Researchers report a new two-drug regimen could speed up harvesting of hematopoietic stem cells for transplantation and yield a population of cells that engraft more efficiently than those produced by standard regimens. In a paper...